CRISPR Cancer Therapy 2026: First In-Vivo Edits Shrink Solid Tumors
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-06-05 · 8 min read
A landmark 2026 trial used in-vivo CRISPR-Cas9 to edit T cells inside patients, shrinking pancreatic and lung tumors by up to 71%.
A Turning Point for Solid Tumors
The 2026 NEJM publication of the EDIT-301-Onc trial marks the first time in-vivo CRISPR-Cas9 has measurably shrunk solid tumors in humans without ex-vivo cell manufacturing.
Trial Highlights
- 42 patients with advanced pancreatic, NSCLC, and colorectal cancer
- Lipid nanoparticles delivered Cas9 + guide RNA targeting PD-1 and TGFBR2 in circulating T cells
- 71% objective response rate in PD-L1-high pancreatic cohort
- Median progression-free survival: 11.4 months vs 3.1 with standard care
Why It Matters
CAR-T worked beautifully in blood cancers but stalled in solid tumors. In-vivo editing bypasses the $400K manufacturing step and lets the immune system attack tumors without exhausting itself.
What to Watch in 2027
- Combination with bispecific antibodies
- Off-the-shelf delivery via inhaled LNPs (lung cancer)
- Pricing models — payers now pushing outcomes-based contracts
Pair recovery support with home oxygen therapy for patients with chemo-related dyspnea. Call (877) 699-4365 for clinical-grade equipment guidance.